Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 1, 2008, Pages 1-4

  Soriano, Vincent ^a   Perelson, Alan S ^b   Zoulim, Fabien ^c  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

HBV; HCV; Resistance mechanisms

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; EMTRICITABINE; ENTECAVIR; INTERFERON; LAMIVUDINE; TELBIVUDINE; TENOFOVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CHRONIC HEPATITIS; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; EDITORIAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL TOLERANCE; MONOTHERAPY; MUTATION RATE; NONHUMAN; OPEN READING FRAME; TARGET CELL; VIRION; VIRUS GENOME; VIRUS MUTATION; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN;

DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; SELECTION (GENETICS);

EID: 45749088957     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn175     Document Type: Editorial

References (34)

1. Soriano V, Puoti M, Bonacini M et al. Care of patients with chronic hepatitis B and HIV co-infection: Recommendations from an HIV-HBV international panel. AIDS 2005; 19: 221-40.
2. Soriano V, Puoti M, Sulkowski M et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 1073-89.
3. Perelson A, Neumann A, Markowitz M et al. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 1582-6.
4. Neumann A, Lam N, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alpha therapy. Science 1998; 282: 103-7.
5. Tsiang M, Rooney J, Toole J et al. Biphasic clearance kinetics of hepatitis B Virus from patients during adefovir dipivoxil therapy. Hepatology 1999; 29: 1863-9.
6. Murray J, Purcell R, Wieland S. The half-life of hepatitis B virions. Hepatology 2006; 44: 1117-21.
7. Markowitz M, Louis M, Hurley A et al. A novel antiviral intervention results in more accurate assessment of HIV-1 replication dynamics and T-cell decay in vivo. J Virol 2003; 77: 5037-8.
8. Neumann A, Lam N, Dahari H et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28-35.
9. Ramratnam B, Bonhoeffer S, Binley J et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999; 354: 1782-5.
10. Nowak M, Bonhoeffer S, Hill A et al. Viral-dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996; 93: 4398-402.
11. Perelson A, Essunger P, Ho D. Dynamics of HIV-1 and CD4+ lymphocytes in vivo. AIDS 1997; 11 Suppl A: 17-24.
12. Moraleda. G, Saputelli J, Aldrich G et al. Lack of effect of antiviral therapy in non-dividing hepatocyte cultures on the closed circular DNA of the woodcheck hepatitis virus. J Virol 1997; 71 9392-9.
13. Werle-Lapostolle B, Bowden S, Locarnini S et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126 1750-8.
14. Guo J, Bichko V, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol 2001; 75: 8516-23.
15. Dahari H, Ribeiro R, Rice C et al. Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. J Virol 2007; 81: 750-60.
16. Tisdale M, Kemp S, Parry N et al. Rapid in vitro selection of HIV type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993; 90: 5653-6.
17. Lai C, Chien R, Leung N et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-8.
18. Litwin S, Toll E, Albert A et al. The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: Theoretical considerations. J Clin Virol 2005; 34 Suppl 1: 96-107.
19. Summers J, Jilbert A, Yang W et al. Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci USA 2003; 100: 11652-9.
20. Lewin S, Ribeiro R, Walters T et al. Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed. Hepatology 2001; 34: 1012-20.
21. Locarnini S. Molecular virology and the development of resistant mutants: Implications for therapy. Semin Liver Dis 2005; 25 Suppl 1: 9-19.
22. Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008; 61: 766-8.
23. Villet S, Pichoud C, Billioud G et al. Impact of hepatitis B virus rt181 V/T mutants on hepatitis B treatment failure. J Hepatol 2008; 48: 747-55.
24. Petravic J, Loh L, Kent S et al. CD4+ target cell availability determines the dynamics of immune escape and reversion in vivo. J Virol 2008; 82: 4091-101.
25. Kuntzen T, Timm J, Berical A et al. Viral sequence evolution in acute hepatitis C virus infection. J Virol 2007; 81: 11658-68.
26. Lau G, Cooksley H, Ribeiro R et al. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antivir Ther 2007; 12: 705-18.
27. Torres-Ibarra R, Cano-Dominguez C. Sustained virological response after more than 3 years of the end of treatment with conventional alpha-2b or pegylated alpha-2a interferon. J Hepatol 2007; 46 Suppl 1: 247.
28. Maylin S, Martinot-Peignoux M, Boyer N et al. Sustained virological response is associated with eradication of HCV and decrease in anti-HCV titer in patients treated for chronic hepatitis C with interferon alpha-2b or pegylated interferon alpha-2b plus ribavirin. Hepatology 2007; 46 Suppl 1: 343-4.
29. Soriano V, Maida I, Nuñez M et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antivir Ther 2004; 9: 987-92.
30. Berenguer J, Alvarez-Pellicer J, Lopez-Aldeguer J et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in HIV/HCV co-infected patients. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, 2008. Abstract 60. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
31. Soriano V, Madejon A, Vispo E et al. Emerging drugs for hepatitis C. Expert Opin Emerg Drugs 2008; 13: 1-19.
32. Gish R, Lok A, Chang T et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-44.
33. Tan J, Degertekin B, Wong S et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48: 391-8.
34. Reijnders J, Janssen H. Potency of tenofovir in chronic hepatitis B: mono or combination therapy? J Hepatol 2008; 48: 383-6.